malignant tumor
Conditions
Interventions
WHSC2-103 peptide is intradermaly injected and subsequently Hisamitsu adjuvant LA3% is pasted. The patient also received personalized peptide vaccin formula with Montanide ISA51VG. The vaccins are adm
Sponsors
Kurume University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient meets all of the followings: 1) malignat tumor 2) more than 4-weeks past after the previous molecular targetting or chemotherapy 3) Performance status 0 or 1 4) HLA-A2 positive 5) IgG reactive to WHSC2-103 is positive and at least one more posiitive of vaccine panel peptides 6) expected life is more than 3 months 7) WBC more than 2,500/mm3 Lymphocyte more than 900/mm3 Hemoglobin more than 8.0 g/dL Platelet more than 50,000/mm3 Creatinin less than 2.0mg/dL Total bilirubin less than 2.5mg/dL 8) age more than 20 years old 9) acquisition of informed consent
Exclusion criteria
Exclusion criteria: Patient meets the followings: 1) under or have a plan of treatment with molecular tagetting or chemotherapy during this study 2) other severe diseases 3) severe allagic dideases 4) sensitive to adhesive plaster 5) woman with plegnancy or under milk feeding, man who is not accept contaception 6) doctor consider who is not appropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of adeverse events using CTCAE v.4.0 | — |
Secondary
| Measure | Time frame |
|---|---|
| Peptide-specigic IgG and CTL response after 6th vaccination | — |
Countries
Japan
Contacts
Public Contactnot specified
Kurume University Cancer vaccine center
Outcome results
None listed